Cat. No. HS-515 003 |
50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
Applications | |
Immunogen | Synthetic peptide corresponding to residues surrounding AA 315 of mouse CD55 (UniProt Id: Q61475) |
Reactivity |
Reacts with: mouse (Q61475). No signal: rat, human. Other species not tested yet. |
Data sheet | hs-515_003.pdf |
CD55, also known as Complement Decay-Accelerating Factor or DAF, is a glycosylphosphatidylinositol (GPI)-linked membrane inhibitor of the complement system (1). While humans and other mammalian species have only one DAF gene, the mouse has two separate, highly homologous DAF genes in its genome. One gene encodes a GPI-anchored DAF protein that is similar to human DAF (GPI-DAF), and the other gene encodes a molecule that is incorporated into the membrane via a transmembrane domain (TM-DAF) (2). TM-DAF gene expression is restricted to the testis (2,3) whereas the GPI-DAF molecule is found on leukocytes, erythrocytes and serum-exposed stromal cells. CD55 acts as a complement inhibitor via inactivation of C3 convertases, splitting them into their individual proteins and preventing their assembly (4). In addition, CD55 is a binding partner for CD97 (also known as ADGRE5), which is widely expressed in monocytes, granulocytes, lymphocytes, macrophages, dendritic cells and smooth muscle cells and also in a variety of tumors (4). CD55 is particularly upregulated during inflammatory conditions to prevent tissue damage. Its expression is associated with several diseases, including cancer, malaria, protein-losing enteropathy, paroxysmal nocturnal hemoglobinuria, multiple sclerosis and rheumatoid arthritis (4).